• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ADRX
Share

ADARx Pharmaceuticals Stocks

¤ 0Last Updated 25.09.2026

Issuer Rating

Performance

Risk

Recommendation

Sell

¤ 0
Key Takeaways

Risk factor

Profitability factor

Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

25.09.2026 15:00

ADARx IPO: A developer of treatments for rare diseases and an AbbVie partner has gone public

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.09.2026 15:45

"Hacker Club" Incidents: How Errors in AI Tests Created New Risks for Investors

25.09.2026 15:30

BlackRock sees Kazakhstan and Uzbekistan as new investment hubs

25.09.2026 15:20

Morning in New York: Inflation Expectations in the Spotlight

25.09.2026 15:00

ADARx IPO: A developer of treatments for rare diseases and an AbbVie partner has gone public

25.09.2026 14:58

It's Not Just Chips: Morgan Stanley Advises Investors to Prepare Their Portfolios for a New Cycle of AI Development

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026